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The 58th Annual Meeting of the American Society for
Human Genetics (ASHG) gathered experts in all areas of
genetics and genomics from around the world. In total, there
were nearly 5,000 people registered for the meeting this
year. The meeting is one of the best opportunities for
geneticists to catch up on the latest research breakthroughs,
but also presents an excellent setting for meeting old friends
and colleagues in the field. This year’s meeting also saw an
increase in the number of exhibitor booths, clearly demon-
strating how genetics is going mainstream in the health care
industry.
One of the best attended sessions was the presidential
address, delivered by ASHG President Aravinda Chakravarti
(Johns Hopkins University, Baltimore, USA) [Session 1]. In
his talk, entitled ‘Principia Genetica: our future science’,
Chakravarti outlined the great achievements made in
genetics to date, but also reminded us that there is plenty of
work ahead. He emphasized that we must take full
advantage of the knowledge gleaned from the large genome
projects and to use this towards understanding the basic
mechanisms of our genome. Chakravarti stated that great
progress has been made in describing the genome and
genetic variation, but we now need to go from description to
prediction. Only when the basic mechanisms of our genome
are well understood will we be able to take that step. He also
cautioned that there have been many unexpected findings in
the genome in the past decade - for example, the low number
of genes, the large amounts of variation, the complexity of
transcriptional regulation - and our genome probably has a
few more surprises in store for us in the future.
In terms of new discoveries and trends in the field, there
were four major themes in which significant progress has
been made over the last year. The success of identification of
variants associated with complex traits using genome-wide
association studies (GWASs) has been established over the
past two years. This year, one major theme was that data
from several of the main cohorts in the initial wave of
GWASs had been pooled, leading to better power to detect
novel loci. As an example, the GIANT consortium study of
body mass index, presented by Cristen Willer (University of
Michigan, Ann Arbor, USA) [Abstract 105], made an initial
meta-analysis of 13 cohorts of over 32,000 individuals,
followed by a replication in over 58,000 samples from 14
independent studies. These types of meta-analysis,
performed for many common diseases, identified many new
risk alleles. There was also a trend among the GWAS
presentations to study non-disease-related traits, such as
height, or traits indirectly linked to disease, for example,
blood-lipid and cholesterol levels. Two of the key messages
coming out of the GWASs were that many of the genes
identified would not have been on anyone’s list of candidates
and also that the variants identified explain a very small
fraction of the overall disease burden in the population.
There was also agreement on the challenges that lie ahead,
namely how we best use this knowledge of low-penetrance
risk alleles and how this knowledge can be translated into
clinical utility.
Another area in which major progress has been made is in
the field of structural variation, and specifically copy
number variation (CNV). Since the discoveries that this type
of variation is abundant in the human genome werepublished, the interest in making better CNV maps and
linking CNVs to disease has grown rapidly. This year, there
were over 200 abstracts related to this form of variation and
the session entitled ‘Structural variation and disease’ was
one of the most popular. Don Conrad and Emmanouil
Dermitzakis, both from the Wellcome Trust Sanger
Institute (Hinxton, UK) [Abstracts 150, 149], described
large collaborative efforts towards better annotating CNVs
at high resolution with better information about variation
boundaries, population frequencies and breakpoint
mechanisms. The main purpose of creating better CNV
maps is to enable studies of the correlation of CNV with
human traits. It was clear from the meeting that ample
progress is already being made in this area. Several talks
were focused on the characterization of CNVs in patient
cohorts, describing associations with various forms of
cancer, schizophrenia and Crohn’s disease. It is likely that
this will remain a hot topic over the next few years,
especially when CNVs can be used in a better way in GWAS
designs.
In terms of complex traits, one of the most challenging areas
is to understand the etiology of neuropsychiatric disorders.
This year, this field of research received plenty of attention,
with two sessions on neuropsychiatric disorders and two
sessions related to autism. Several important genetic
discoveries over the past years have led to an increased
understanding of the complexity of these disorders. The
studies of CNV in neuropsychiatric disorders in general, and
in autism and schizophrenia in particular, have led to the
discovery of specific genes and loci that are strongly
associated or directly causative. Large collaborative efforts to
study the genetics of autism were reported in several talks.
Jim Sutcliffe (Vanderbilt University, Nashville, USA)
[Abstract 220], representing the Autism Genome Project,
gave an update on the progress of phase II of the project,
which is a study using high-resolution single nucleotide
polymorphism (SNP) arrays in a large cohort of autism trios.
Maja Bucan (University of Pennsylvania, Philadelphia, USA)
[Abstract 219], representing a collaboration mainly involving
University of Pennsylvania and the Children’s Hospital of
Philadelphia (USA), used a similar strategy but on a
different set of samples. Both studies are using the array
data for both SNP-based and CNV-based analysis. A theme
that has been emerging over the past year and that was
reiterated in the presentations this year is that these
disorders can be caused by a large number of genes.
However, although many of the genes and CNVs identified
seem to have very high penetrance, each locus seems to
make a very small contribution to the total patient
population. Despite this low contribution overall, these are
extremely important findings as they represent targets that
can be used to untangle the complex pathways involved.
The most dramatic development since last year’s ASHG
meeting has been the completion of several individual human
genome sequences. Not only has this led to an increased
understanding of individual genome variation, but it has given
us a glimpse of the future of genomics. Personalized genome
sequencing was one of the main topics of the meeting and was
discussed in depth both in the genomics and the ethical, legal
and social issues sessions. Two of the highlights of the
individual genome sequencing talks were delivered by David
Altshuler (The Broad Institute, Boston, USA) [Abstract 84]
and Craig Venter (J Craig Venter Institute, Rockville, USA)
[Abstract 37], respectively. Altshuler gave a presentation on
the aims, design and progress of the ‘1000 Genomes’ Project.
This is a two year project with the goal of sequencing 1,000 or
more individual genomes to create a detailed map of human
genetic variation. The pilot phase, which aims to answer
questions about what strategies and approaches to use for the
next stage of the project, is now well underway. In a separate
session entitled ‘Presidential Symposium: genome stories’,
Craig Venter gave a talk entitled ‘My genome’ [Abstract 37].
Venter, who is one of only two identified individuals who have
had their genome sequences published so far (along with
James Watson of Cold Spring Harbor Laboratory, Cold Spring
Harbor, USA), gave a very personal account of the
characterization of his own genetic code and the implications
this has had for himself. There have only been four individual
genome sequences published to date. It will be interesting to
see what that number is by the time of next year’s ASHG
meeting.
The feeling I came home with after the 5 days filled with
presentations, meetings and vendor lunch seminars was that
the increased pace and reduced cost of producing large amounts
of genomic data have led to impressive progress over the past
year, but as a result data analysis is becoming a bottleneck, and
making sense of the results is the real challenge. The stage we
are currently at in genomics research, taking the impressive
achievements over the past year into account, was summarized
nicely by ASHG president Aravinda Chakravarti, who stated
that “We live in a very different world in genetics than we did a
short time ago. Clearly we have exciting times ahead.”
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ASHG, American Society for Human Genetics; CNV, copy
number variation; GWAS, genome-wide association study;
SNP, single nucleotide polymorphism.
A Ac ck kn no ow wl le ed dg ge em me en nt ts s
All abstracts in the reference list were presented at the annual meeting
of The American Society of Human Genetics, November 11-15, 2008,
Philadelphia, Pennsylvania, USA [1]. 
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